Long-tErm Follow-uP of antithrombotIc Management Patterns In Acute CORonary Syndrome Patients in Asia
Completed
- Conditions
- Acute Coronary Syndrome
- Registration Number
- NCT01361386
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to describe the short-and long-tern (i.e. up to 2 years following the index event) AMPs in patients hospitalized for an acute coronary syndrome (i.e. STEMI or NSTE-ACS), and to document clinical outcomes, economic aspects and impact on quality of life of these AMPs in a 'real-life' setting.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 13011
Inclusion Criteria
- Written informed consent has been provided.
- Diagnosis of STEMI, NSTEMI or UA
- Hospitalization for the first time within 48 hours of onset of symptoms.
Exclusion Criteria
- UA, STEMI, NSTEMI precipitated by or as a complication of surgery, trauma, or GI bleeding or post-PCI UA, STEMI and NSTEMI occurring in patients already hospitalized for other reasons.
- Current participation in a randomised interventional clinical trial.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method short- and long-term medication and treatment prescribed by physicians in real-life setting up to 3 years
- Secondary Outcome Measures
Name Time Method clinical outcome (Cardiovascular events) up to 3 years quality of life (EQ-5D questionnaire) up to 3 years cost of hospitalization up to 3 years
Trial Locations
- Locations (1)
Research Site
🇻🇳Hue, Vietnam